CA3064299A1 - Treatment of depressive disorders - Google Patents

Treatment of depressive disorders Download PDF

Info

Publication number
CA3064299A1
CA3064299A1 CA3064299A CA3064299A CA3064299A1 CA 3064299 A1 CA3064299 A1 CA 3064299A1 CA 3064299 A CA3064299 A CA 3064299A CA 3064299 A CA3064299 A CA 3064299A CA 3064299 A1 CA3064299 A1 CA 3064299A1
Authority
CA
Canada
Prior art keywords
gaboxadol
pharmaceutical composition
parenteral administration
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3064299A
Other languages
English (en)
French (fr)
Inventor
Matthew During
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ovid Therapeutics Inc
Original Assignee
Ovid Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ovid Therapeutics Inc filed Critical Ovid Therapeutics Inc
Publication of CA3064299A1 publication Critical patent/CA3064299A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA3064299A 2017-05-24 2018-05-22 Treatment of depressive disorders Pending CA3064299A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762510481P 2017-05-24 2017-05-24
US62/510,481 2017-05-24
US15/933,673 US20180338959A1 (en) 2017-05-24 2018-03-23 Treatment of depressive disorders
US15/933,673 2018-03-23
PCT/US2018/033848 WO2018217718A1 (en) 2017-05-24 2018-05-22 Treatment of depressive disorders

Publications (1)

Publication Number Publication Date
CA3064299A1 true CA3064299A1 (en) 2019-11-29

Family

ID=64395877

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3064299A Pending CA3064299A1 (en) 2017-05-24 2018-05-22 Treatment of depressive disorders

Country Status (10)

Country Link
US (4) US20180338959A1 (https=)
EP (2) EP3630065A4 (https=)
JP (2) JP2020520963A (https=)
KR (1) KR20200018485A (https=)
CN (2) CN115105499A (https=)
AU (1) AU2018272819A1 (https=)
CA (1) CA3064299A1 (https=)
IL (1) IL270781A (https=)
MX (1) MX393452B (https=)
WO (1) WO2018217718A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11597726B2 (en) 2020-05-20 2023-03-07 Certego Therapeutics Inc. Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2015002252A (es) 2012-08-21 2015-07-21 Sage Therapeutics Inc Metodos para tratar epilepsia o estado de epilepsia.
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
HK1258616A1 (zh) 2016-03-08 2019-11-15 Sage Therapeutics, Inc. 神经活性类固醇、组合物、及其用途
US10987303B2 (en) * 2018-05-02 2021-04-27 LifeMax Laboratories, Inc. Extended release suspension formulation of lurasidone
US11123332B2 (en) 2018-11-21 2021-09-21 Certego Therapeutics Inc. Gaboxadol for reducing risk of suicide and rapid relief of depression
WO2020168337A1 (en) 2019-02-17 2020-08-20 Magid Abraham Compositions and methods for treatment of depression and other disorders
KR102085938B1 (ko) * 2019-11-04 2020-03-06 한국메탈실리콘 주식회사 실리콘 복합체 제조방법

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK270278A (da) 1977-06-20 1978-12-21 Krogsgaard Larsen P Cycliske aminosyrer
US4362731A (en) 1980-09-01 1982-12-07 Sandoz Ltd. Myotonolytic use of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridin-3-ol and derivatives thereof
US4353910A (en) 1981-11-27 1982-10-12 Kefalas A/S Derivatives of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridine-3-one, pharmaceutical compositions and methods of treatment
AR031473A1 (es) * 2000-11-20 2003-09-24 Lundbeck & Co As H Intensificadores de gaba en el tratamiento de enfermedades relacionadas con una reducida actividad neuroesteroide
US20020165217A1 (en) * 2001-05-01 2002-11-07 Pfizer Inc. Combination treatment for anxiety and depression
DK1641456T3 (da) * 2003-06-25 2010-06-21 Lundbeck & Co As H Gaboxadol til behandling af depression og andre affektive lidelser
CL2004001603A1 (es) * 2003-06-25 2005-05-27 Lundbeck & Co As H Uso de gabaxadol para preparar un medicamento util para el tratamiento del dolor neuropatico.
US20050234093A1 (en) * 2003-06-25 2005-10-20 H. Lundbeck A/S Treatment of depression and other affective disorders
JP2007530604A (ja) 2004-04-02 2007-11-01 ハー・ルンドベック・アクチエゼルスカベット 呼吸機能障害の治療
US20090048288A1 (en) * 2007-08-13 2009-02-19 H. Lundbeck A/S Method of treating stress-mediated depression
US10628156B2 (en) * 2013-07-09 2020-04-21 Texas Instruments Incorporated Vector SIMD VLIW data path architecture
DK3151832T3 (da) * 2014-06-06 2021-06-14 Ovid Therapeutics Inc Fremgangsmåder til øgning af tonisk hæmning og behandling af sekundær søvnløshed
IL256912B2 (en) * 2015-07-17 2024-01-01 Ovid Therapeutics Inc Methods of treating developmental disorders with gaboxadol
WO2017027249A1 (en) * 2015-08-11 2017-02-16 Ovid Therapeutics Inc. Methods of sedation and parenteral formulation for use during critical care treatment
KR20220035195A (ko) * 2019-07-15 2022-03-21 오비드 테라퓨틱스 인크. 치료적 치료를 위한 가복사돌을 포함하는 약학적 제제

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11597726B2 (en) 2020-05-20 2023-03-07 Certego Therapeutics Inc. Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders

Also Published As

Publication number Publication date
EP3630065A1 (en) 2020-04-08
EP3939587A1 (en) 2022-01-19
US20180338959A1 (en) 2018-11-29
US20190117633A1 (en) 2019-04-25
KR20200018485A (ko) 2020-02-19
AU2018272819A1 (en) 2019-12-05
JP2020520963A (ja) 2020-07-16
CN110996910A (zh) 2020-04-10
US20210379028A1 (en) 2021-12-09
US20200179351A1 (en) 2020-06-11
JP2023061957A (ja) 2023-05-02
WO2018217718A1 (en) 2018-11-29
MX2019014024A (es) 2020-02-17
EP3630065A4 (en) 2021-03-24
MX393452B (es) 2025-03-24
IL270781A (en) 2020-01-30
CN115105499A (zh) 2022-09-27

Similar Documents

Publication Publication Date Title
US20210379028A1 (en) Treatment of depressive disorders
US12109201B2 (en) Methods and compositions for treatment of epileptic disorders
TWI763632B (zh) 用於重症治療時之鎮靜方法及非口服調配物
WO2017027249A1 (en) Methods of sedation and parenteral formulation for use during critical care treatment
CN107961215B (zh) 一种左西替利嗪注射剂
US20200138785A1 (en) Use of gaboxadol, ganaxolone and allopregnanolone to treat movement disorders
HK40027257A (en) Treatment of depressive disorders
HK1256349A1 (zh) 用於在危重监护治疗期间使用的镇静方法和肠胃外制剂

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20230516

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-2-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20241122

N11 Application terminated

Free format text: ST27 STATUS EVENT CODE: T-6-6-N10-N11-N106 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION NOT REINSTATED BY DEADLINE

Effective date: 20251124

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251230